Mylan SA and Meridian Medical Technologies, a Pfizer subsidiary, have issued an urgent recall of their EpiPen injector, which is used by patients who have allergies, saying there was a defect with the device. Used for anaphylaxis in patients, which is triggered by insect bites, or stings, and allergic reactions, the EpiPen auto injector comes in both junior and senior doses and retails at about R1,000 per device. In an emergency situation, it could be deadly for patients to not have properly functioning devices and they could suffer serious health consequences. Mylan SA head of strategic projects Tanya Anhaeusser said the voluntary recall was a precautionary measure to safeguard patients after incidents in the US and Asia during which two devices were reported to be faulty and the needles were unable to inject the amount of fluid that was necessary. In both incidents, the company said, the contents of the devices were normal, but the actual devices were defective and there was a "po...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.